论文部分内容阅读
目的 :明确早期应用尼莫地平对弥漫性轴索损伤 (DAI)的疗效和安全性。方法 :根据特征性的弥漫性轴索损伤 (DAI)影像学诊断标准 ,60名颅脑外伤患者被诊断为DAI而进入这项开放平行对照试验。结果 :研究证实 :尼莫地平治疗是安全的 ,患者的耐受性较好。外伤后 3月两组在优良效果上进行比较 ,尼莫地平组优于对照组 ,但无显著性差异。在Ⅲ级DAI患者亚组中 ,尼莫地平治疗DAI的显著有效性得到了体现 (P <0 0 5 )。经TCD检查发现在本组中脑血管痉挛的发生率较高 ( 4 0 % )。结论 :临床上早期应用尼莫地平对DAI是有价值的。在DAI的临床治疗中 ,防止脑缺血性损伤仍然是重要治疗目标之一
Objective: To clarify the efficacy and safety of early application of nimodipine on diffuse axonal injury (DAI). METHODS: Sixty patients with traumatic brain injury were diagnosed with DAI and entered the open-label parallel controlled trial, based on the characteristic diffuse axonal injury (DAI) diagnostic criteria. Results: The study confirmed that: nimodipine treatment is safe, patients with better tolerance. After trauma in March two groups were compared on the excellent results, nimodipine group was better than the control group, but no significant difference. In the subgroup of patients with grade III DAI, the significant efficacy of nimodipine in the treatment of DAI was demonstrated (P <0.05). TCD examination found in this group of cerebral vasospasm higher incidence (40%). Conclusion: Nimodipine is valuable for DAI early in clinic. In the clinical treatment of DAI, to prevent cerebral ischemic injury is still one of the important treatment goals